Global Infantile Spasms Therapeutics Market to Grow 10% by 2021: Analysis By Dosage Form & ROA - Research and Markets

DUBLIN, Jan 13, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Infantile Spasms Therapeutics Market 2017-2021" report to their offering.

The report forecasts the global infantile spasms therapeutics market to grow at a CAGR of 10.16% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

The new trend observed in the infantile spasms market is the development of seizure alert devices that detects the seizure and notifies it to the physician, through alarms, phone calls, or text messages. SmartMonitor has developed a watch, SmartWatch, which should be worn 24 hours a day to detect any seizures. If it detects any seizures, it immediately sends out an alert warning to the caregivers/physicians. The device is now available only in the US.

Also, Empatica has developed another smart watch, Embrace, which monitors the physiological stress, arousal, sleep, and physical activity of the individual. Apart from this, a smartphone application EpDetect has been developed, which exploits advanced signal processing to detect seizures. Once a seizure is detected, the application will inform the caregiver about the status of the patient along with the global positioning system (GPS) location. Similarly, BioLert has also developed EpiLert, which is an alert device with GPS and text messaging systems.

According to the report, special regulatory designations such as fast track designations and orphan drugs designation assigned to the drugs by the US FDA and the EMA help in the faster entry of these drugs into the market. Fast track designations are assigned to the drugs used in the treatment of serious conditions with high unmet need prevailing in the market. Similarly, orphan drug designations are assigned for the drugs used in the treatment of rare diseases. These designations help in the faster approval process for the drugs and help in early entry into the market.

Key Vendors:

• H. Lundbeck
• Mallinckrodt Pharmaceuticals
• INSYS Therapeutics
  

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Infantile spasm: Overview

Part 06: Market landscape

Part 07: Market segmentation by dosage form

Part 08: Market segmentation by ROA

Part 09: Geographical segmentation

Part 10: Market drivers

Part 11: Impact of drivers

Part 12: Market challenges

Part 13: Impact of drivers and challenges

Part 14: Market trends

Part 15: Vendor landscape

Part 16: Key vendor analysis

Part 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/l6d8nb/global_infantile

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]